Hansa Biopharma AB (SE0002148817) — research page
SE · se-cm-kg/XSTO/SE0002148817 · as of 2026-11-06
Identity and listing
The issuer is Hansa Biopharma AB, listed on Nasdaq Stockholm, with ticker SE0002148817, ISIN SE0002148817 and LEI 549300LLEO25ZJJ3NT91. Security type, segment, sector and jurisdiction are not on the record. Listing status is listed, not halted.
| field | value | source · read date |
|---|---|---|
| name | Hansa Biopharma AB | source · 2026-11-06 |
| exchange | Nasdaq Stockholm | source · 2026-11-06 |
| ticker | SE0002148817 | source · 2026-11-06 |
| ISIN | SE0002148817 | source · 2026-11-06 |
| LEI | 549300LLEO25ZJJ3NT91 | source · 2026-11-09 |
| security type | not on the record | |
| segment | not on the record | |
| sector | not on the record | |
| jurisdiction | not on the record | |
| status | listed, not halted | source · 2026-11-09 |
The disclosure read
The record holds 108 filings in the twelve months to 2026-11-06, across 51 filing days. The median gap between filing days is 5.0 days. The latest filing is dated 2026-11-05 and is of type Investor News, 1 day before the record date. The median gap on Nasdaq Stockholm is 9.5 days across 398 issuers, against 5.0 days for this issuer; the median filings count there is 30.0 and the median latency is 7.0 days. Sector peer figures are not on the record for this market.
| filings | median gap between filing days | days from latest filing to as-of | |
|---|---|---|---|
| this issuer | 108 | 5 | 1 |
| exchange median: Nasdaq Stockholm (398 issuers) | 30 | 9.5 | 7 |
| date | type | category | filing |
|---|---|---|---|
| 2026-11-05 | Investor News | Investor News | Hansa Biopharma presenterar vid Stifel 2026 Healthcare Conference |
| 2026-11-05 | Investor News | Investor News | Hansa Biopharma presenting at Stifel 2026 Healthcare Conference |
| 2026-11-04 | Investor News | Investor News | Hansa Biopharma to participate in BIO-Europe 2026 |
| 2026-11-04 | Investor News | Investor News | Hansa Biopharma deltar i BIO-Europe 2026 |
| 2026-10-30 | Investor News | Investor News | Hansa Biopharma to participate in the BioStock Life Science Summit |
window 2025-11-06 to 2026-11-06 · the node's disclosure lines, as get_filings serves them
Auditor
The auditor of record is not on the record, and its location is not on the record. Auditor changes are not on the record, as this register has no lifecycle type map yet.
Events and halts
Listing, delisting, name change, domicile change and segment move are not on the record, as this register has no lifecycle type map yet. The halt flag shows listed, not halted.
Orderability
The orderability outcome is not determinable. The chapter's orderability section carries no client categories, so the outcome cannot name its client category. The rule version is acm-68000/se/mifid-ii-product-governance/r1, and the chapter is as of 2026-11-04.
rule acm-68000/se/mifid-ii-product-governance/r1 · chapter as of 2026-11-04 · the full outcome: get_orderability
Coverage
The issuer's investor-relations page names 9 research houses: SEB, ABG Sundal Collier, Van Lanschot Kempen, Carnegie, H.C. Wainwright & Co., William Blair, Leerink Partners LLC, Jefferies LLC and Wedbush Securities.
| research house | analyst | source · read date |
|---|---|---|
| SEB | Christopher Uhde | issuer page · 2026-11-12 |
| ABG Sundal Collier | Alexander Krämer | issuer page · 2026-11-12 |
| Van Lanschot Kempen | Chiara Montironi | issuer page · 2026-11-12 |
| Carnegie | Erik Hultgård | issuer page · 2026-11-12 |
| H.C. Wainwright & Co. | Douglas Tsao | issuer page · 2026-11-12 |
| William Blair | Matt Phipps | issuer page · 2026-11-12 |
| Leerink Partners LLC | Thomas J. Smith | issuer page · 2026-11-12 |
| Jefferies LLC | Farzin Haque, Ph.D. | issuer page · 2026-11-12 |
| Wedbush Securities | David Nierengarten, Ph.D. | issuer page · 2026-11-12 |
Open research
No openly published research notes were found for the issuer.
Licensed
Licensed research: none loaded. A licensed row is served only to an agent whose firm holds that licence (licensor, entitlement). No licensed row is loaded.
| licensor | entitlement | title | date | source |
|---|---|---|---|---|
| none loaded |
As-of depth
The market's vintage is not sealed. No issuer years are sealed, the market's earliest sealed date is not on the record, and the live record began is not on the record.
Sources
7 source pages are named on this page; every value above carries its own source page and read date in the numbers.
- 10.1
- https://firds.esma.europa.eu/firds/ (identity.exchange)
- 10.2
- https://mapping.gleif.org/api/v2/isin-lei/latest/download (identity.lei)
- 10.3
- https://mcp.se-cm-kg.ai/events/XSTO/SE0002148817 (the disclosure lines)
- 10.4
- https://api.news.eu.nasdaq.com/news/query.action?globalGroup=exchangeNotice&globalName=ExchangenewsFilter|FirstNorthInformation (the halt flag)
- 10.5
- https://se.eu-cm-kg.ai/book/aio.json (the orderability chapter)
- 10.6
- https://www.hansabiopharma.com/investors/analysts/ (coverage)
- 10.7
- https://mcp.se-cm-kg.ai/record/XSTO/SE0002148817 (the record)
Read it by agent
The same page, signed and receipted: get_research at https://mcp.getresearch.ai/mcp with {"isin":"SE0002148817"}. Twins: .md · .json. Written: Claude through the platform account, Haiku class; one pass; checked against the numbers. Page hash sha256:90f995b911e36f19.